


DAVID Y. IGE  
GOVERNOR



CATHY BETTS  
DIRECTOR

JOSEPH CAMPOS II  
DEPUTY DIRECTOR

STATE OF HAWAII  
**DEPARTMENT OF HUMAN SERVICES**

P. O. Box 339  
Honolulu, Hawaii 96809-0339

December 21, 2020

The Honorable Ronald D. Kouchi,  
President and Members of the Senate  
Thirty-First State Legislature  
State Capitol, Room 409  
Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker  
and Members of the House of  
Representatives  
Thirty-First State Legislature  
State Capitol, Room 431  
Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Enclosed is the following report submitted in accordance with section 346-59.9, Hawaii Revised Statutes, on psychotropic medication.

In accordance with section 93-16, HRS, the report is available to review electronically at the Department's website, at <https://humanservices.hawaii.gov/reports/legislative-reports/>.

Sincerely,

Cathy Betts  
Director

Enclosure

C:

Governor's Office  
Lieutenant Governor's Office  
Department of Budget & Finance  
Legislative Auditor  
Legislative Reference Bureau Library (1 hard copy)

President Kouchi, Speaker Saiki

December 21, 2020

Page 2

Hawaii State Public Library, System State Publications Distribution Center (2 hard copies, 1 electronic copy)

Hamilton Library, Serials Department, University of Hawaii (1 hard copy)

REPORT TO THE THIRTY-FIRST HAWAII STATE  
LEGISLATURE 2021

IN ACCORDANCE WITH THE PROVISIONS OF  
SECTION 346-59.9, HAWAII REVISED STATUTES,  
ON PSYCHOTROPIC MEDICATION

DEPARTMENT OF HUMAN SERVICES  
MED-QUEST DIVISION  
DECEMBER 2020

**2019 ANNUAL REPORT ON PSYCHOTROPIC MEDICATION,  
SECTION 346-59.9, HAWAII REVISED STATUTES**

Act 102, Session Laws of Hawaii (SLH) 2012, amended section 346-59.9, Hawaii Revised Statutes (HRS), Psychotropic Medication. Section 346-59.9 (g), HRS, requires the Department of Human Services to report annually on:

- (1) The number of brand-name and generic prescriptions written to which this section applies; and
- (2) The amount expended on brand-name prescriptions and the amount expended on generic prescriptions written each fiscal year to which this section applies.

The information is provided in the tables below. The data is as reported by each QUEST Integration (QI) health plan, the Community Care Services (CCS) contractor, and the Fee-For-Service (FFS) program.

**Hawaii Medicaid Psychotropic Cost for State Fiscal Year (SFY) 2020**

Includes QI Health Plans, CCS and FFS

|                             | Total Number of Claims |     |         |      | Total Expenditure |     |             |     |
|-----------------------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|
|                             | Brand                  |     | Generic |      | Brand             |     | Generic     |     |
|                             | #                      | %   | #       | %    | \$                | %   | \$          | %   |
| <b>Antipsychotic Total</b>  |                        |     |         |      |                   |     |             |     |
| 7/1/2015-6/30/2016          | 9,337                  | 19% | 40,019  | 81%  | \$11,145,728      | 54% | \$9,491,857 | 46% |
| 7/1/2016-6/30/2017          | 12,807                 | 18% | 58,477  | 82%  | \$18,984,689      | 69% | \$8,628,201 | 31% |
| 7/1/2017-6/30/2018*         | 13,548                 | 19% | 57,354  | 81%  | \$23,654,762      | 85% | \$4,225,052 | 15% |
| 7/1/2018-6/30/2019*         | 15,356                 | 21% | 58,278  | 79%  | \$27,848,873      | 88% | \$3,731,913 | 12% |
| 7/1/2019-6/30/2020          | 16,478                 | 21% | 63,320  | 79%  | \$29,825,940      | 90% | \$3,180,142 | 10% |
| <b>Antidepressant Total</b> |                        |     |         |      |                   |     |             |     |
| 7/1/2015-6/30/2016          | 3,559                  | 3%  | 111,133 | 97%  | \$1,042,335       | 31% | \$2,284,742 | 69% |
| 7/1/2016-6/30/2017          | 4,381                  | 3%  | 138,676 | 97%  | \$1,390,375       | 39% | \$2,199,437 | 61% |
| 7/1/2017-6/30/2018*         | 3,703                  | 3%  | 138,633 | 97%  | \$1,388,243       | 39% | \$2,172,979 | 61% |
| 7/1/2018-6/30/2019*         | 4,085                  | 3%  | 133,805 | 97%  | \$1,552,521       | 43% | \$2,046,890 | 57% |
| 7/1/2019-6/30/2020          | 4,005                  | 3%  | 142,526 | 97%  | \$1,607,878       | 45% | \$1,992,669 | 55% |
| <b>Anti-anxiety Total</b>   |                        |     |         |      |                   |     |             |     |
| 7/1/2015-6/30/2016          | 158                    | <1% | 57,220  | 100% | \$84,757          | 16% | \$442,140   | 84% |
| 7/1/2016-6/30/2017          | 221                    | <1% | 62,667  | 100% | \$95,637          | 17% | \$471,682   | 83% |
| 7/1/2017-6/30/2018*         | 58                     | <1% | 53,064  | 100% | \$80,206          | 19% | \$341,808   | 81% |
| 7/1/2018-6/30/2019*         | 36                     | <1% | 49,022  | 100% | \$78,615          | 20% | \$307,168   | 80% |
| 7/1/2019-6/30/2020          | 37                     | <1% | 51,036  | 100% | \$74,476          | 20% | \$298,112   | 80% |

\*Changes of last year's reported claim count and percentages are due to various health plans' correction of data.

The total expenditure for psychotropic medication in SFY 2020 is approximately \$36,979,000. This total includes the QI health plans (\$21,728,000), CCS (\$15,228,000) program, and the FFS program (\$23,000).

**AlohaCare QUEST Integration Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |           |      | Total No. Unique Utilizers |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-----------|------|----------------------------|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic   |      |                            |
|                       | #                      | %   | #       | %    | \$                | %   | \$        | %    |                            |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |           |      |                            |
| 7/1/09-6/30/10        | 5,887                  | 85% | 1,022   | 15%  | \$2,182,797       | 94% | \$141,089 | 6%   | 1,259                      |
| 7/1/10-6/30/11        | 6,545                  | 81% | 1,460   | 19%  | \$2,915,457       | 94% | \$183,521 | 6%   | 1,410                      |
| 7/1/11-6/30/12        | 5,062                  | 64% | 2,887   | 36%  | \$2,614,657       | 83% | \$523,881 | 17%  | 1,392                      |
| 7/1/12-6/30/13        | 3,517                  | 46% | 4,138   | 54%  | \$1,951,363       | 80% | \$484,644 | 20%  | 1,220                      |
| 7/1/13-6/30/14        | 2,703                  | 40% | 4,010   | 60%  | \$2,323,691       | 86% | \$365,329 | 14%  | 1,088                      |
| 7/1/14-6/30/15        | 1,550                  | 34% | 3,021   | 66%  | \$1,404,173       | 86% | \$224,212 | 14%  | 907                        |
| 7/1/15-6/30/16        | 785                    | 16% | 4,067   | 84%  | \$794,990         | 52% | \$743,892 | 48%  | 926                        |
| 7/1/16-6/30/17        | 922                    | 16% | 4,748   | 84%  | \$1,072,207       | 61% | \$679,612 | 39%  | 966                        |
| 7/1/17-6/30/18        | 965                    | 17% | 4,582   | 83%  | \$1,355,938       | 71% | \$544,753 | 29%  | 907                        |
| 7/1/18-6/30/19        | 1,249                  | 20% | 4,997   | 80%  | \$2,005,402       | 82% | \$433,982 | 18%  | 979                        |
| 7/1/19-6/30/20        | 1,285                  | 20% | 5,089   | 80%  | \$2,177,743       | 81% | \$509,351 | 19%  | 1,058                      |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |           |      |                            |
| 7/1/09-6/30/10        | 4,380                  | 26% | 12,376  | 74%  | \$602,689         | 59% | \$423,742 | 41%  | 3,355                      |
| 7/1/10-6/30/11        | 3,580                  | 20% | 14,613  | 80%  | \$509,803         | 46% | \$607,128 | 54%  | 3,623                      |
| 7/1/11-6/30/12        | 2,303                  | 12% | 16,663  | 88%  | \$375,886         | 38% | \$621,367 | 62%  | 3,593                      |
| 7/1/12-6/30/13        | 1,913                  | 10% | 17,247  | 90%  | \$274,955         | 36% | \$489,987 | 64%  | 3,314                      |
| 7/1/13-6/30/14        | 712                    | 4%  | 17,915  | 96%  | \$170,763         | 24% | \$553,019 | 76%  | 3,192                      |
| 7/1/14-6/30/15        | 259                    | 2%  | 16,857  | 98%  | \$61,252          | 17% | \$366,514 | 83%  | 3,182                      |
| 7/1/15-6/30/16        | 291                    | 2%  | 18,202  | 98%  | \$78,660          | 20% | \$321,469 | 80%  | 3,263                      |
| 7/1/16-6/30/17        | 374                    | 2%  | 19,255  | 98%  | \$109,221         | 22% | \$385,603 | 78%  | 3,298                      |
| 7/1/17-6/30/18        | 324                    | 2%  | 18,603  | 98%  | \$121,565         | 21% | \$463,865 | 79%  | 3,132                      |
| 7/1/18-6/30/19        | 365                    | 2%  | 17,131  | 98%  | \$154,742         | 28% | \$397,926 | 72%  | 2,956                      |
| 7/1/19-6/30/20        | 392                    | 2%  | 17,378  | 98%  | \$166,932         | 26% | \$469,196 | 74%  | 3,020                      |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |           |      |                            |
| 7/1/09-6/30/10        | 15                     | <1% | 8,206   | 100% | \$2,505           | 3%  | \$79,318  | 97%  | 1,786                      |
| 7/1/10-6/30/11        | 18                     | <1% | 8,111   | 100% | \$1,951           | 2%  | \$80,947  | 98%  | 1,894                      |
| 7/1/11-6/30/12        | 2                      | <1% | 8,362   | 100% | \$247             | <1% | \$93,660  | 100% | 1,835                      |
| 7/1/12-6/30/13        | 0                      | 0%  | 6,731   | 100% | \$0               | 0%  | \$61,849  | 100% | 1,734                      |
| 7/1/13-6/30/14        | 28                     | <1% | 11,583  | 100% | \$8,176           | 6%  | \$138,556 | 94%  | 2,290                      |
| 7/1/14-6/30/15        | 16                     | <1% | 11,658  | 100% | \$5,809           | 4%  | \$139,536 | 96%  | 3,058                      |
| 7/1/15-6/30/16        | 54                     | <1% | 12,269  | 100% | \$20,744          | 10% | \$182,755 | 90%  | 2,968                      |
| 7/1/16-6/30/17        | 0                      | 0%  | 8,411   | 100% | \$0               | 0%  | \$104,935 | 100% | 2,847                      |
| 7/1/17-6/30/18*       | 0                      | 0%  | 7,155   | 100% | \$0               | 0%  | \$92,363  | 100% | 2,605                      |
| 7/1/18-6/30/19*       | 0                      | 0%  | 6,180   | 100% | \$0               | 0%  | \$76,404  | 100% | 1,432                      |
| 7/1/19-6/30/20        | 0                      | 0%  | 5,909   | 100% | \$0               | 0%  | \$81,327  | 100% | 1,428                      |

\*Changes for 7/1/17-6/30/18\* reported data are due to health plan's correction of data: removal of Food and Drug Administration (FDA) approved benzodiazepines for seizure or insomnia diagnoses. Change for 7/1/18-6/30/19\* from last year's reported data is due to health plan's correction of data.

**HMSA QUEST Integration Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |             |     | Total No. Unique Utilizers |  |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|----------------------------|--|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic     |     |                            |  |
|                       | #                      | %   | #       | %    | \$                | %   | \$          | %   |                            |  |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |             |     |                            |  |
| 7/1/09-6/30/10        | 11,615                 | 83% | 2,430   | 17%  | \$4,319,335       | 96% | \$160,146   | 4%  | 2,127*                     |  |
| 7/1/10-6/30/11        | 11,406                 | 80% | 2,810   | 19%  | \$4,847,964       | 98% | \$103,154   | 2%  | 2,171                      |  |
| 7/1/11-6/30/12        | 9,978                  | 66% | 5,290   | 34%  | \$5,009,526       | 88% | \$664,503   | 12% | 2,221                      |  |
| 7/1/12-6/30/13        | 7,586                  | 44% | 9,642   | 56%  | \$4,626,576       | 86% | \$768,865   | 14% | 2,469                      |  |
| 7/1/13-6/30/14        | 7,055                  | 45% | 8,755   | 55%  | \$5,011,583       | 90% | \$555,836   | 10% | 2,429                      |  |
| 7/1/14-6/30/15        | 6,074                  | 41% | 8,770   | 59%  | \$4,866,243       | 89% | \$598,551   | 11% | 2,214                      |  |
| 7/1/15-6/30/16        | 3,458                  | 20% | 13,895  | 80%  | \$3,029,597       | 60% | \$2,003,703 | 40% | 2,439                      |  |
| 7/1/16-6/30/17        | 3,129                  | 17% | 15,743  | 83%  | \$3,313,766       | 62% | \$1,999,102 | 38% | 2,629                      |  |
| 7/1/17-6/30/18        | 3,494                  | 17% | 17,278  | 83%  | \$4,292,902       | 77% | \$1,309,563 | 23% | 2,901                      |  |
| 7/1/18-6/30/19        | 4,180                  | 19% | 17,873  | 81%  | \$5,715,478       | 81% | \$1,306,238 | 19% | 2,984                      |  |
| 7/1/19-6/30/20        | 4,679                  | 20% | 18,656  | 80%  | \$6,670,627       | 86% | \$1,061,545 | 14% | 3,017                      |  |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |             |     |                            |  |
| 7/1/09-6/30/10        | 8,864                  | 27% | 24,262  | 73%  | \$1,185,654       | 58% | \$875,185   | 42% | 5,565*                     |  |
| 7/1/10-6/30/11        | 7,410                  | 19% | 30,843  | 81%  | \$1,004,692       | 51% | \$947,123   | 49% | 6,199                      |  |
| 7/1/11-6/30/12        | 5,237                  | 13% | 35,348  | 87%  | \$904,502         | 54% | \$781,470   | 46% | 6,442                      |  |
| 7/1/12-6/30/13        | 3,870                  | 8%  | 43,422  | 92%  | \$902,444         | 51% | \$880,628   | 49% | 7,428                      |  |
| 7/1/13-6/30/14        | 2,376                  | 5%  | 46,341  | 95%  | \$620,624         | 42% | \$871,708   | 58% | 7,895                      |  |
| 7/1/14-6/30/15        | 2,279                  | 4%  | 50,516  | 96%  | \$562,786         | 38% | \$909,438   | 62% | 8,276                      |  |
| 7/1/15-6/30/16        | 2,622                  | 4%  | 57,011  | 96%  | \$756,377         | 49% | \$783,261   | 51% | 8,893                      |  |
| 7/1/16-6/30/17        | 2,812                  | 4%  | 62,578  | 96%  | \$884,042         | 50% | \$888,569   | 50% | 9,509                      |  |
| 7/1/17-6/30/18        | 2,533                  | 4%  | 68,823  | 96%  | \$902,682         | 47% | \$1,027,492 | 53% | 10,151                     |  |
| 7/1/18-6/30/19        | 2,828                  | 4%  | 67,376  | 96%  | \$1,033,062       | 51% | \$991,503   | 49% | 10,015                     |  |
| 7/1/19-6/30/20        | 2,625                  | 4%  | 68,462  | 96%  | \$1,009,268       | 54% | \$855,341   | 46% | 9,880                      |  |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |             |     |                            |  |
| 7/1/09-6/30/10        | 18                     | <1% | 11,536  | 100% | \$5,910           | 4%  | \$137,248   | 96% | 2,360*                     |  |
| 7/1/10-6/30/11        | 31                     | <1% | 13,316  | 100% | \$6,803           | 6%  | \$111,448   | 94% | 2,667                      |  |
| 7/1/11-6/30/12        | 18                     | <1% | 13,545  | 100% | \$4,540           | 4%  | \$116,889   | 96% | 2,488                      |  |
| 7/1/12-6/30/13        | 34                     | <1% | 17,584  | 100% | \$10,378          | 8%  | \$118,503   | 92% | 3,606                      |  |
| 7/1/13-6/30/14        | 44                     | <1% | 21,076  | 100% | \$18,801          | 14% | \$115,739   | 86% | 4,461                      |  |
| 7/1/14-6/30/15        | 30                     | <1% | 22,374  | 100% | \$37,788          | 29% | \$92,723    | 71% | 4,979                      |  |
| 7/1/15-6/30/16        | 24                     | <1% | 24,761  | 100% | \$60,906          | 43% | \$81,824    | 57% | 5,374                      |  |
| 7/1/16-6/30/17        | 50                     | <1% | 22,777  | 100% | \$73,147          | 46% | \$86,197    | 54% | 5,205                      |  |
| 7/1/17-6/30/18        | 43                     | <1% | 23,457  | 100% | \$75,622          | 47% | \$86,971    | 53% | 5,317                      |  |
| 7/1/18-6/30/19        | 29                     | <1% | 20,985  | 100% | \$72,926          | 47% | \$80,873    | 53% | 4,850                      |  |
| 7/1/19-6/30/20        | 27                     | <1% | 20,334  | 100% | \$72,684          | 51% | \$69,524    | 49% | 4,496                      |  |

\*The change of a pharmacy claims processor during this period results in some inconsistencies in data sets.

**Kaiser QUEST Integration Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |           |      | Total No. Unique Utilizers |  |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-----------|------|----------------------------|--|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic   |      |                            |  |
|                       | #                      | %   | #       | %    | \$                | %   | \$        | %    |                            |  |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |           |      |                            |  |
| 7/1/09-6/30/10        | 714                    | 53% | 628     | 47%  | \$210,251         | 98% | \$3,932   | 2%   | 289                        |  |
| 7/1/10-6/30/11        | 853                    | 54% | 730     | 46%  | \$301,307         | 98% | \$6,176   | 2%   | 360                        |  |
| 7/1/11-6/30/12        | 625                    | 38% | 1,023   | 62%  | \$258,603         | 89% | \$32,444  | 11%  | 372                        |  |
| 7/1/12-6/30/13        | 404                    | 24% | 1,307   | 76%  | \$204,739         | 92% | \$17,232  | 8%   | 335                        |  |
| 7/1/13-6/30/14        | 391                    | 24% | 1,251   | 76%  | \$242,048         | 94% | \$16,517  | 6%   | 321                        |  |
| 7/1/14-6/30/15        | 252                    | 22% | 905     | 78%  | \$197,867         | 75% | \$65,471  | 25%  | 353                        |  |
| 7/1/15-6/30/16        | 49                     | 3%  | 1,379   | 97%  | \$48,694          | 27% | \$134,555 | 73%  | 417                        |  |
| 7/1/16-6/30/17        | 109                    | 5%  | 1,972   | 95%  | \$102,231         | 66% | \$52,436  | 34%  | 416                        |  |
| 7/1/17-6/30/18        | 134                    | 7%  | 1,860   | 93%  | \$186,140         | 84% | \$36,781  | 16%  | 455                        |  |
| 7/1/18-6/30/19*       | 160                    | 7%  | 2,090   | 93%  | \$310,786         | 87% | \$45,384  | 13%  | 500                        |  |
| 7/1/19-6/30/20        | 198                    | 9%  | 2,036   | 91%  | \$363,754         | 88% | \$49,195  | 12%  | 500                        |  |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |           |      |                            |  |
| 7/1/09-6/30/10        | 497                    | 8%  | 5,857   | 92%  | \$75,263          | 66% | \$38,422  | 34%  | 1,181                      |  |
| 7/1/10-6/30/11        | 463                    | 6%  | 6,968   | 94%  | \$80,249          | 66% | \$41,292  | 34%  | 1,378                      |  |
| 7/1/11-6/30/12        | 485                    | 5%  | 8,444   | 95%  | \$107,488         | 66% | \$55,350  | 34%  | 1,589                      |  |
| 7/1/12-6/30/13        | 458                    | 5%  | 7,943   | 95%  | \$124,731         | 71% | \$51,058  | 29%  | 1,398                      |  |
| 7/1/13-6/30/14        | 248                    | 4%  | 6,811   | 96%  | \$82,406          | 52% | \$77,015  | 49%  | 1,358                      |  |
| 7/1/14-6/30/15        | 20                     | <1% | 5,582   | 100% | \$8,669           | 14% | \$51,510  | 86%  | 1,524                      |  |
| 7/1/15-6/30/16        | 37                     | <1% | 6,143   | 100% | \$17,195          | 30% | \$39,477  | 70%  | 1,721                      |  |
| 7/1/16-6/30/17        | 85                     | 1%  | 9,044   | 99%  | \$28,566          | 35% | \$53,950  | 65%  | 1,695                      |  |
| 7/1/17-6/30/18        | 102                    | 1%  | 7,660   | 99%  | \$38,854          | 43% | \$51,103  | 57%  | 1,722                      |  |
| 7/1/18-6/30/19*       | 110                    | 2%  | 7,022   | 98%  | \$55,713          | 50% | \$56,203  | 50%  | 1,749                      |  |
| 7/1/19-6/30/20        | 74                     | 1%  | 7,215   | 99%  | \$75,710          | 59% | \$53,247  | 41%  | 1,835                      |  |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |           |      |                            |  |
| 7/1/09-6/30/10        | 1                      | <1% | 2,469   | 100% | \$147             | 3%  | \$4,851   | 97%  | 648                        |  |
| 7/1/10-6/30/11        | 1                      | <1% | 2,789   | 100% | \$661             | 11% | \$5,101   | 89%  | 777                        |  |
| 7/1/11-6/30/12        | 15                     | <1% | 2,972   | 100% | \$5,503           | 53% | \$4,915   | 47%  | 867                        |  |
| 7/1/12-6/30/13        | 13                     | <1% | 2,646   | 100% | \$4,555           | 53% | \$4,095   | 47%  | 758                        |  |
| 7/1/13-6/30/14        | 13                     | <1% | 2,374   | 100% | \$6,912           | 65% | \$3,746   | 35%  | 760                        |  |
| 7/1/14-6/30/15        | 2                      | <1% | 2,758   | 100% | \$50              | 1%  | \$3,843   | 99%  | 898                        |  |
| 7/1/15-6/30/16        | 1                      | <1% | 3,403   | 100% | \$48              | <1% | \$11,032  | 100% | 1,041                      |  |
| 7/1/16-6/30/17        | 3                      | <1% | 3,539   | 100% | \$69              | <1% | \$17,336  | 100% | 986                        |  |
| 7/1/17-6/30/18        | 11                     | <1% | 3,227   | 100% | \$2,926           | 14% | \$17,332  | 86%  | 950                        |  |
| 7/1/18-6/30/19        | 1                      | <1% | 2,842   | 100% | \$4               | <1% | \$16,936  | 100% | 879                        |  |
| 7/1/19-6/30/20        | 1                      | <1% | 2,971   | 100% | \$2               | 0%  | \$15,026  | 100% | 867                        |  |

\*Change from last year's reported data is due to health plan's correction of data.

**Ohana Health Quest Integration Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |             |      | Total No. Unique Utilizers |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-------------|------|----------------------------|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic     |      |                            |
|                       | #                      | %   | #       | %    | \$                | %   | \$          | %    |                            |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 15,653                 | 76% | 5,068   | 24%  | \$7,510,115       | 92% | \$645,522   | 8%   | 1,944                      |
| 7/1/10-6/30/11        | 18,771                 | 76% | 6,008   | 24%  | \$10,069,923      | 93% | \$701,013   | 7%   | 2,164                      |
| 7/1/11-6/30/12        | 15,357                 | 58% | 11,280  | 42%  | \$9,537,668       | 75% | \$3,122,545 | 25%  | 2,129                      |
| 7/1/12-6/30/13        | 9,555                  | 35% | 17,735  | 65%  | \$7,532,671       | 66% | \$3,936,457 | 34%  | 2,216                      |
| 7/1/13-6/30/14        | 1,123                  | 8%  | 12,628  | 92%  | \$1,274,736       | 28% | \$3,234,847 | 72%  | 1,691                      |
| 7/1/14-6/30/15        | 3,837                  | 27% | 10,398  | 73%  | \$3,747,958       | 62% | \$2,273,132 | 38%  | 1,757                      |
| 7/1/15-6/30/16        | 1,115                  | 15% | 6,303   | 85%  | \$1,271,849       | 38% | \$2,080,960 | 62%  | 1,295                      |
| 7/1/16-6/30/17        | 1,795                  | 12% | 12,834  | 88%  | \$2,682,837       | 60% | \$1,807,174 | 40%  | 1,745                      |
| 7/1/17-6/30/18*       | 2,066                  | 17% | 10,443  | 83%  | \$3,885,963       | 94% | \$258,783   | 6%   | 1,476                      |
| 7/1/18-6/30/19*       | 1,816                  | 14% | 11,050  | 86%  | \$3,488,316       | 89% | \$450,085   | 11%  | 1,501                      |
| 7/1/19-6/30/20        | 1,633                  | 12% | 11,737  | 88%  | \$2,913,134       | 80% | \$716,415   | 20%  | 1,562                      |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 5,462                  | 26% | 15,688  | 74%  | \$786,111         | 60% | \$519,290   | 40%  | 2,559                      |
| 7/1/10-6/30/11        | 5,335                  | 22% | 19,287  | 78%  | \$754,409         | 49% | \$800,750   | 51%  | 2,846                      |
| 7/1/11-6/30/12        | 4,310                  | 16% | 22,277  | 84%  | \$736,653         | 49% | \$774,715   | 51%  | 2,856                      |
| 7/1/12-6/30/13        | 2,561                  | 9%  | 24,647  | 91%  | \$631,605         | 42% | \$881,158   | 58%  | 2,904                      |
| 7/1/13-6/30/14        | 239                    | 1%  | 22,163  | 99%  | \$67,074          | 9%  | \$679,477   | 91%  | 3,241                      |
| 7/1/14-6/30/15        | 548                    | 2%  | 22,174  | 98%  | \$128,668         | 12% | \$983,688   | 88%  | 3,403                      |
| 7/1/15-6/30/16        | 214                    | 2%  | 11,183  | 98%  | \$50,611          | 9%  | \$502,401   | 91%  | 2,418                      |
| 7/1/16-6/30/17        | 481                    | 2%  | 21,422  | 98%  | \$139,268         | 28% | \$354,343   | 72%  | 3,119                      |
| 7/1/17-6/30/18*       | 294                    | 2%  | 17,271  | 98%  | \$113,069         | 45% | \$135,963   | 55%  | 2,530                      |
| 7/1/18-6/30/19*       | 383                    | 2%  | 18,037  | 98%  | \$128,739         | 44% | \$166,880   | 56%  | 2,601                      |
| 7/1/19-6/30/20        | 349                    | 2%  | 19,248  | 98%  | \$114,451         | 33% | \$232,462   | 67%  | 2,763                      |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 76                     | <1% | 18,057  | 100% | \$21,672          | 11% | \$171,815   | 89%  | 2,931                      |
| 7/1/10-6/30/11        | 49                     | <1% | 19,805  | 100% | \$17,288          | 8%  | \$191,471   | 92%  | 3,032                      |
| 7/1/11-6/30/12        | 48                     | <1% | 21,810  | 100% | \$18,985          | 8%  | \$207,492   | 92%  | 3,128                      |
| 7/1/12-6/30/13        | 51                     | <1% | 18,104  | 100% | \$22,898          | 12% | \$173,596   | 88%  | 2,838                      |
| 7/1/13-6/30/14        | 208                    | 2%  | 12,765  | 98%  | \$120,112         | 52% | \$108,888   | 48%  | 2,482                      |
| 7/1/14-6/30/15        | 419                    | 3%  | 13,056  | 97%  | \$153,167         | 51% | \$148,628   | 49%  | 2,529                      |
| 7/1/15-6/30/16        | 66                     | 1%  | 6,458   | 99%  | \$2,260           | 3%  | \$73,627    | 97%  | 1,743                      |
| 7/1/16-6/30/17        | 106                    | 1%  | 11,477  | 99%  | \$3,550           | 5%  | \$62,813    | 95%  | 2,337                      |
| 7/1/17-6/30/18*       | 0                      | 0%  | 7,721   | 100% | \$0               | 0%  | \$45,565    | 100% | 1,702                      |
| 7/1/18-6/30/19*       | 0                      | 0%  | 8,518   | 100% | \$0               | 0%  | \$45,072    | 100% | 1,825                      |
| 7/1/19-6/30/20        | 0                      | 0%  | 9,633   | 100% | \$0               | 0%  | \$42,779    | 100% | 1,974                      |

\*Change from last year's reported data is due to health plan's correction of data.



**United HealthCare QUEST Integration Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |             |      | Total No. Unique Utilizers |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-------------|------|----------------------------|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic     |      |                            |
|                       | #                      | %   | #       | %    | \$                | %   | \$          | %    |                            |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 7,268                  | 71% | 3,010   | 29%  | \$5,724,344       | 92% | \$500,395   | 8%   | 2,045                      |
| 7/1/10-6/30/11        | 6,953                  | 72% | 2,743   | 28%  | \$7,049,618       | 95% | \$395,039   | 5%   | 1,634                      |
| 7/1/11-6/30/12        | 5,760                  | 58% | 4,046   | 42%  | \$6,084,993       | 85% | \$1,032,928 | 15%  | 1,493                      |
| 7/1/12-6/30/13        | 3,052                  | 35% | 5,691   | 65%  | \$4,532,005       | 83% | \$902,203   | 17%  | 1,593                      |
| 7/1/13-6/30/14        | 2,132                  | 34% | 4,212   | 66%  | \$3,219,152       | 92% | \$290,152   | 8%   | 1,500                      |
| 7/1/14-6/30/15        | 1,663                  | 30% | 3,798   | 70%  | \$2,809,915       | 89% | \$358,261   | 11%  | 1,183                      |
| 7/1/15-6/30/16        | 914                    | 16% | 4,635   | 84%  | \$1,998,940       | 62% | \$1,216,051 | 38%  | 1,211                      |
| 7/1/16-6/30/17        | 980                    | 16% | 5,040   | 84%  | \$2,421,887       | 71% | \$1,003,613 | 29%  | 1,316                      |
| 7/1/17-6/30/18        | 983                    | 15% | 5,505   | 85%  | \$3,096,142       | 82% | \$669,871   | 18%  | 1,455                      |
| 7/1/18-6/30/19        | 1,061                  | 17% | 5,170   | 83%  | \$3,132,677       | 87% | \$484,258   | 13%  | 1,461                      |
| 7/1/19-6/30/20        | 1,834                  | 17% | 8,721   | 83%  | \$3,317,460       | 93% | \$251,829   | 7%   | 1,400                      |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 3,001                  | 28% | 7,765   | 72%  | \$736,113         | 64% | \$417,611   | 36%  | 2,697                      |
| 7/1/10-6/30/11        | 1,931                  | 20% | 7,954   | 80%  | \$539,340         | 56% | \$426,176   | 44%  | 2,093                      |
| 7/1/11-6/30/12        | 1,146                  | 11% | 9,024   | 89%  | \$357,022         | 56% | \$285,514   | 44%  | 1,979                      |
| 7/1/12-6/30/13        | 719                    | 8%  | 8,865   | 92%  | \$340,744         | 56% | \$272,948   | 44%  | 2,301                      |
| 7/1/13-6/30/14        | 425                    | 5%  | 8,550   | 95%  | \$217,360         | 46% | \$258,976   | 54%  | 2,519                      |
| 7/1/14-6/30/15        | 147                    | 2%  | 9,031   | 98%  | \$81,075          | 21% | \$297,782   | 79%  | 2,532                      |
| 7/1/15-6/30/16        | 120                    | 1%  | 9,392   | 99%  | \$710,044         | 24% | \$223,818   | 76%  | 2,598                      |
| 7/1/16-6/30/17        | 79                     | 1%  | 9,530   | 99%  | \$45,018          | 16% | \$231,109   | 84%  | 2,665                      |
| 7/1/17-6/30/18*       | 67                     | 1%  | 10,268  | 99%  | \$35,584          | 11% | \$281,214   | 89%  | 2,768                      |
| 7/1/18-6/30/19        | 77                     | 1%  | 9,572   | 99%  | \$55,273          | 17% | \$267,264   | 83%  | 2,731                      |
| 7/1/19-6/30/20        | 261                    | 2%  | 15,854  | 98%  | \$116,053         | 31% | \$257,994   | 69%  | 2,755                      |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |             |      |                            |
| 7/1/09-6/30/10        | 183                    | <1% | 2,062   | 99%  | \$10,627          | 5%  | \$189,657   | 95%  | 2,640                      |
| 7/1/10-6/30/11        | 107                    | <1% | 12,415  | 99%  | \$11,423          | 5%  | \$223,875   | 95%  | 2,880                      |
| 7/1/11-6/30/12        | 70                     | <1% | 12,729  | 99%  | \$9,734           | 5%  | \$196,624   | 95%  | 2,813                      |
| 7/1/12-6/30/13        | 16                     | <1% | 9,578   | 100% | \$6,208           | 4%  | \$144,976   | 96%  | 2,779                      |
| 7/1/13-6/30/14        | 8                      | <1% | 6,748   | 100% | \$4,166           | 6%  | \$61,766    | 94%  | 1,917                      |
| 7/1/14-6/30/15        | 1                      | <1% | 7,123   | 100% | \$724             | 1%  | \$49,736    | 99%  | 1,949                      |
| 7/1/15-6/30/16        | 1                      | <1% | 7,020   | 100% | \$78              | <1% | \$53,372    | 100% | 2,029                      |
| 7/1/16-6/30/17        | 0                      | 0%  | 6,261   | 100% | \$0               | 0%  | \$58,868    | 100% | 1,907                      |
| 7/1/17-6/30/18        | 4                      | <1% | 5,763   | 100% | \$1,658           | 2%  | \$68,219    | 98%  | 1,873                      |
| 7/1/18-6/30/19        | 5                      | <1% | 5,294   | 100% | \$5,220           | 8%  | \$58,498    | 92%  | 1,798                      |
| 7/1/19-6/30/20        | 2                      | <1% | 7,031   | 100% | \$327             | 1%  | \$64,736    | 99%  | 1,818                      |

**Community Care Services (CCS) Psychotropic Cost**

|                       | Total Number of Claims |     |         |      | Total Expenditure |     |             |     | Total No. Unique Utilizers |
|-----------------------|------------------------|-----|---------|------|-------------------|-----|-------------|-----|----------------------------|
|                       | Brand                  |     | Generic |      | Brand             |     | Generic     |     |                            |
|                       | #                      | %   | #       | %    | \$                | %   | \$          | %   |                            |
| <b>Antipsychotic</b>  |                        |     |         |      |                   |     |             |     |                            |
| 7/1/14-6/30/15        | 8,485                  | 33% | 17,085  | 67%  | \$9,467,667       | 71% | \$3,950,018 | 29% | 2,365                      |
| 7/1/15-6/30/16        | 3,017                  | 24% | 9,741   | 76%  | \$4,003,135       | 55% | \$3,312,697 | 45% | 1,997                      |
| 7/1/16-6/30/17        | 5,873                  | 24% | 18,146  | 76%  | \$9,390,255       | 75% | \$3,088,022 | 25% | 2,149                      |
| 7/1/17-6/30/18*       | 5,904                  | 25% | 17,464  | 74%  | \$10,836,432      | 89% | \$1,405,482 | 11% | 2,143                      |
| 7/1/18-6/30/19        | 6,556                  | 28% | 16,996  | 72%  | \$12,738,445      | 93% | \$1,016,616 | 7%  | 2,055                      |
| 7/1/19-6/30/20        | 6,831                  | 29% | 17,079  | 71%  | \$14,360,161      | 96% | \$591,757   | 4%  | 2,134                      |
| <b>Antidepressant</b> |                        |     |         |      |                   |     |             |     |                            |
| 7/1/14-6/30/15        | 622                    | 3%  | 19,924  | 97%  | \$159,353         | 15% | \$916,810   | 85% | 2,167                      |
| 7/1/15-6/30/16        | 277                    | 3%  | 9,206   | 97%  | \$67,713          | 14% | \$416,698   | 86% | 1,695                      |
| 7/1/16-6/30/17        | 548                    | 3%  | 16,715  | 97%  | \$183,952         | 39% | \$289,616   | 61% | 1,785                      |
| 7/1/17-6/30/18        | 396                    | 2%  | 15,958  | 98%  | \$181,865         | 46% | \$213,552   | 54% | 1,712                      |
| 7/1/18-6/30/19        | 295                    | 2%  | 14,678  | 98%  | \$124,992         | 43% | \$167,099   | 57% | 1,565                      |
| 7/1/19-6/30/20        | 304                    | 2%  | 14,355  | 98%  | \$125,464         | 50% | \$123,937   | 50% | 1,585                      |
| <b>Anti-anxiety</b>   |                        |     |         |      |                   |     |             |     |                            |
| 7/1/14-6/30/15        | 16                     | <1% | 6,734   | 100% | \$1,347           | 2%  | \$81,480    | 98% | 1,044                      |
| 7/1/15-6/30/16        | 12                     | <1% | 3,226   | 100% | \$721             | 2%  | \$40,043    | 98% | 758                        |
| 7/1/16-6/30/17        | 32                     | <1% | 6,047   | 100% | \$3,505           | 8%  | \$38,221    | 92% | 899                        |
| 7/1/17-6/30/18*       | 0                      | 0%  | 5,713   | 100% | \$0               | 0%  | \$31,250    | 99% | 876                        |
| 7/1/18-6/30/19        | 1                      | <1% | 5,204   | 100% | \$464             | 2%  | \$29,389    | 98% | 855                        |
| 7/1/19-6/30/20        | 7                      | <1% | 5,158   | 100% | \$1,464           | 6%  | \$24,719    | 94% | 823                        |

\*Change from last year’s reported data is due to health plan’s correction of data.

**Discussion**

This State Fiscal Year (SFY) 2018-2019 report utilizes the term “QUEST Integration” to reflect the Medicaid managed care health plans for SFY 2019. The data is as reported by each QI health plan, CCS contractor and FFS program.

Prior to this Act 205, SLH 2010<sup>1</sup> effective on July 1, 2011, was implemented by the health plans during different quarters in State Fiscal Year (SFY) 2010-2011<sup>2</sup>. SFY 2011-2012, SFY 2012-2013 and SFY 2013-2014 each are a full year of all the plans complying with Act 205 without changes in the law or the program. Trends are noted. Data for SFY 2009-2010, prior to the implementation of Act 205, SLH, is represented for comparison purposes.

Of the five Medicaid health plans and one contractor, three had data updates for 1-2 years prior to SFY 2020.

<sup>1</sup>Access to brand medication is available after two generic failures are documented for antidepressant and anti-anxiety medications. (Section 346-59.9, Hawaii Revised Statutes)

<sup>2</sup>Different approaches and combinations were initiated by the different plans during SFY 2010-2011, such as the following: Preferred Drug Lists/Formulary Coverage, Prospective DUR edits, Point-Of-Sale messaging, Step Therapy, Prior Authorization, Provider Education, and Call Center intervention.

The following trends are noted for SFY 2020:

- 97% of the antidepressant prescriptions are filled with a generic and account for 55% of the antidepressant expenditure. Generic utilization percentage is consistent with data for SFY 2016 through SFY 2020 while the generic expenditure percentage has been decreasing since SFY 2016: 69% to 55%. Health plans utilize various approaches to encourage generic utilization:
  - Before a brand is covered, a trial and failure of two generic antidepressant prescriptions is necessary (Section 346-59.9, HRS).
  - A diagnosis connected to the prescription improves use of FDA approved indications.
  - Generic expenditures are lower due to generic completion driving down the price of the majority of high-volume antidepressant agents.
  - One new brand antidepressant has been approved by the FDA within SFY 2020.
- 100% of the anti-anxiety prescriptions are filled with a generic and account for 80% of the anti-anxiety expenditure. Both brand and generic expenditures have been decreasing since SFY 2017. Although the expenditures are minor when compared to the antidepressant and antipsychotic prescriptions, the decreasing trend may be due to the following:
  - The prescriber may be empowered to prescribe less anti-anxiety medications by the July 2017 enactment of section 329-38, HRS, prescription (c) concerning “Initial concurrent prescriptions for opioids and benzodiazepines shall not be for longer than seven consecutive days unless a supply of longer than seven days is determined to be medically necessary for the treatment of ...”.
  - Diagnosis connected to the prescription improves reporting accuracy (i.e., excludes seizure and insomnia use).
  - The federal SUPPORT Act (beginning October 1, 2020) impacts SFY2020 with required criteria to decrease fraud, misuse, and abuse for concurrent use of anti-anxiety medications and opioids.
- 79% of the antipsychotic prescriptions are filled with a generic. Generic expenditure percentages have been decreasing since SFY 2016: 46% to 10%. The utilization of brand prescriptions percentage remained unchanged in SFY 2020 from SFY 2019 while the brand expenditure trend increased each year since SFY2016: 54% to 90%. Per section 346-59.9, HRS, access to brands are in place or medically necessary use:
  - Brand long-acting injectable dosage forms are higher in expenditures and provide improved adherence rates for high-risk populations. At this time, these have limited generic alternatives.
  - An FDA approved diagnosis code for all branded antipsychotics is required at point of sale (POS) processing to pay a prescription claim at the pharmacy to ensure safety and to deter misuse for some health plans.
  - The SUPPORT Act impacts the SFY2020 report with criteria for concurrent use of antipsychotic medications with opioids and monitoring of antipsychotic use in children: Therapeutic duplication, early refill and age edits as approved by the FDA.